• Kura Oncology outlined updated early-stage trial results for ziftomenib combined with standard intensive induction chemotherapy in newly diagnosed genetically defined acute myeloid leukemia, with data scheduled for oral presentation at European Hematology Association Congress on June 14, 2026.
• Extended follow-up from a 99-patient frontline cohort showed most patients achieved remission, with many reaching deep molecular clearance, supporting durability signals in both NPM1-mutant and KMT2A-rearranged disease.
• Safety profile remained consistent with prior experience, with no new long-term safety signals flagged in the update.
• Company is advancing the regimen into registrational Phase 3 KOMET-017, now enrolling, with management pointing to potential accelerated US regulatory review in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.